Comparison of Three Anti-CCP Antibody Tests and Rheumatoid Factor in RA and Control Patients

Abstract

Sera from 86 RA patients and 90 control patients with other diseases, such as infections, connective tissue diseases, or other rheumatic diseases, were analysed using the four different methods. Specificity (84.4%) and PPV (80.3%) were lowest for RF IgM and highest for EliA CCP (specificity 97.8%, PPV 96.7%), the other values being close to those of EliA CCP. Sensitivity was highest for Quanta Lite CCP (73.3%). Efficiency was highest for Quanta Lite CCP (84.1%) at the lower cut off followed by EliA CCP at both cut offs (83.0%). The discrimination between RA sera (mean value 407.67 U/ml) and control sera (4.54 U/ml) and the relative risk (23.34) were best for EliA CCP. The results of this study reveal that there was no advantage of the anti-CCP antibodies assay applying a new antigen mixture (Quanta Lite CCP 3 ELISA) compared to two second generation anti-CCP antibodies assays (Quanta Lite CCP ELISA and EliA CCP).

Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide 2 antibody and anti-cyclic citrullinated peptide 3 antibody in rheumatoid arthritis

“…We identified 797 articles, of which 17 met the inclusion criteria [25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41]. There were 1952 RA patients selected from Europe, Americas and Asia in the remaining 17 articles that were eventually available for this meta-analysis (see Table 1).…”

Untitled

“…In which 36 had RA. Besides, over the past few years, many studies have evaluated the diagnostic performance of anti-CCP on a variety of diagnostic platform [52][53][54][55][56] .…”

The role of anti-cyclic citrullinated peptide (CCP) antibodies in early detection of rheumatoid arthritis: an overview of the INOVA Diagnostics, Inc. QUANTA Lite CCP assays

“…Correia et al [34] evaluated three techniques for measuring anti-CCP antibodies, including CCP2 and CCP3 ELISAs and a fully automated fluoroenzymeimmunoassay (EliA CCP performed on the ImmunoCAP instrument, Phadia US, Inc.). The specificities were comparable with the three techniques for measuring anti-CCP antibodies, with the automated exactly the same as anti-CCP3 antibodies (96.7%), or slightly higher at a higher cut-off (97.8%) ( Table 3).…”